<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767063</url>
  </required_header>
  <id_info>
    <org_study_id>P13/12_ACTIW</org_study_id>
    <nct_id>NCT02767063</nct_id>
  </id_info>
  <brief_title>Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)</brief_title>
  <acronym>ACTIW</acronym>
  <official_title>Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomized in phase II trials to continue on the same TKI versus one of the&#xD;
      alternative treatment approaches. If a patient is not eligible for one of the treatments, he&#xD;
      (she) will be randomized between the options for which he (she) is eligible.&#xD;
&#xD;
      The trial will start with current available treatment options (experimental arms). New&#xD;
      available treatment options may be open at any times later on. Authorized TKIs are imatinib,&#xD;
      nilotinib, dasatinib, bosutinib and ponatinib.&#xD;
&#xD;
      For all options the treatment duration is for a minimum of 12 months and will be continued in&#xD;
      the absence of adverse events following investigator decision. Each therapeutic option will&#xD;
      be detailed in term of combination modalities, dose, dose adaptation, specific warnings,&#xD;
      specific exclusion and inclusion criteria. The decision to introduce a new option will depend&#xD;
      on the general pace of recruitment and on the assessment of the potential efficacy and safety&#xD;
      of the new treatment, and will be implemented after scientific review by a protocol&#xD;
      amendment.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      A. To select molecules in combination or sequentially with imatinib, nilotinib, dasatinib,&#xD;
      bosutinib or ponatinib potentially able to produce a 25% increase in the Cumulative Incidence&#xD;
      of MR4.5 as compare to control.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      A. To determine the safety of selected therapies&#xD;
&#xD;
      B. To determine the rate of MR4 by 12, 24, 36, 48 months in experimental and control arms&#xD;
&#xD;
      C. To determine the rates of MR4.5 by 24, 36, 48 months in experimental and control arms&#xD;
&#xD;
      D. To determine the rate of undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies)&#xD;
      by 12, 24, 36, 48 months in experimental and control arms&#xD;
&#xD;
      E. To estimate treatment free remission (TFR) in patients eligible for discontinuation&#xD;
      studies&#xD;
&#xD;
      F. To investigate the relationship between biological activity and the clinical efficacy of&#xD;
      the selected therapies&#xD;
&#xD;
      G. To assess the effects of the treatments on the number and clonogenicity of CML stem cells&#xD;
      and other biological markers of interest&#xD;
&#xD;
      H. To estimate duration of response, progression-free survival, event free survival and&#xD;
      overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomised to continue on TKI (same daily dose) versus one of the&#xD;
      alternative novel treatment approaches. If a patient is not eligible for one of the&#xD;
      treatments, he can be randomised for the options for which he is eligible. All treatment&#xD;
      options may be open at all times. Investigators must specify before randomization for which&#xD;
      treatment option they want their patient be included and randomized.&#xD;
&#xD;
      Perspectives New treatment options will be introduced over time. The decision to introduce a&#xD;
      new option will depend on the general pace of recruitment and the assessment of the potential&#xD;
      efficacy and safety of the new treatment in this patient population, and will be implemented&#xD;
      after scientific review by a protocol amendment.&#xD;
&#xD;
      The available treatment arms are:&#xD;
&#xD;
        1. TKI alone same daily dose (control arm)&#xD;
&#xD;
        2. TKI in combination with pioglitazone&#xD;
&#xD;
        3. TKI in combination with Avelumab (anti-PD-L1 antibody)&#xD;
&#xD;
      Planned treatment arms for the future may be :&#xD;
&#xD;
        1. TKI in combination with pegylated interferon&#xD;
&#xD;
        2. TKI in combination with arsenic trioxide&#xD;
&#xD;
        3. TKI in combination with Homoharringtonine&#xD;
&#xD;
      Protocol plan:&#xD;
&#xD;
        1. Control arm (Imatinib, nilotinib, dasatinib, bosutinib or ponatinib):&#xD;
&#xD;
           Daily dose and schedule identical to the daily dose and schedule administered during the&#xD;
           last 3 months&#xD;
&#xD;
        2. Pioglitazone arm&#xD;
&#xD;
             -  TKI : Daily dose and schedule identical to the daily dose and schedule administered&#xD;
                during the last 3 months&#xD;
&#xD;
             -  PIOGLITAZONE (Actos®):&#xD;
&#xD;
                30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2&#xD;
                months in the absence of grade &gt;1 related AE.&#xD;
&#xD;
             -  After 12 Months :&#xD;
&#xD;
           Continue TKI at the same daily dose and STOP pioglitazone.&#xD;
&#xD;
        3. AVELUMAB arm&#xD;
&#xD;
             -  TKI : Daily dose and schedule identical to the daily dose and schedule administered&#xD;
                during the last 3 months&#xD;
&#xD;
             -  AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months'&#xD;
                period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will&#xD;
                be omitted)&#xD;
&#xD;
             -  After 12 Months :Continue TKI at the same daily dose.&#xD;
&#xD;
        4. Other experimental arm TKI : Daily dose and schedule identical to the daily dose and&#xD;
           schedule administered during the last 3 months&#xD;
&#xD;
             -  Arsenic trioxide : to be determined after amendment&#xD;
&#xD;
             -  Pegylated Interferon : to be determined after amendment&#xD;
&#xD;
             -  Homoharringtonine : to be determined after amendment&#xD;
&#xD;
             -  Drug X&#xD;
&#xD;
             -  Drug Y&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of patients achieving a deep molecular response</measure>
    <time_frame>12 months</time_frame>
    <description>The cumulative incidence of patients achieving a deep molecular response defined by MR4.5 or deeper (BCR-ABLIS ≤ 0.0032 %) by 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 Months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms</measure>
    <time_frame>24 months</time_frame>
    <description>The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4.5 by 48 months in experimental and control arms</measure>
    <time_frame>48 months</time_frame>
    <description>The cumulative rate of patients achieving MR4.5 by 48months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 12months in experimental and control arms</measure>
    <time_frame>12 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 12,months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms</measure>
    <time_frame>24 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms</measure>
    <time_frame>48 months</time_frame>
    <description>The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms</measure>
    <time_frame>12 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24months in experimental and control arms</measure>
    <time_frame>24 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24, months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms</measure>
    <time_frame>36 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms</measure>
    <time_frame>48 months</time_frame>
    <description>The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients in treatment free remission during follow-up</measure>
    <time_frame>48 months</time_frame>
    <description>The rate of patients in treatment free remission during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of CML- and normal-CFU in bone marrow by clonogenic assays and RTQ- PCR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>48 months</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>48 months</time_frame>
    <description>duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>48 months</time_frame>
    <description>event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>48 months</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Leukemia, Myeloid, Chronic-Phase</condition>
  <arm_group>
    <arm_group_label>Experimental Arm_ACTOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months&#xD;
PIOGLITAZONE (Actos®):&#xD;
30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade &gt;1 related AE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controled Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm_AVELUMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade &gt;1 related AE.</description>
    <arm_group_label>Experimental Arm_ACTOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)</description>
    <arm_group_label>Experimental Arm_AVELUMAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Common Inclusion Criteria:&#xD;
&#xD;
          1. Patient aged 18y or more&#xD;
&#xD;
          2. Signed informed consent&#xD;
&#xD;
          3. Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL1&#xD;
             transcript positivity at diagnosis&#xD;
&#xD;
          4. Treatment with imatinib, nilotinib, dasatinib or bosutinib for more than 2 years&#xD;
             overall&#xD;
&#xD;
          5. No switch between tyrosine kinase inhibitors within the last 3 months&#xD;
&#xD;
          6. No dose modification within the last 3 months&#xD;
&#xD;
          7. Complete cytogenetic response or BCR-ABL1IS ≤ 1%&#xD;
&#xD;
          8. Detectable BCR-ABL1 with BCR-ABL1IS &gt; 0.0032% (less than MR4.5)&#xD;
&#xD;
          9. ECOG grade 0 to 2&#xD;
&#xD;
         10. ASAT and ALAT ≤ 2.5 N&#xD;
&#xD;
         11. Bilirubin in serum ≤ 2.5 N&#xD;
&#xD;
         12. Men and Women of childbearing potential must be using an adequate method of&#xD;
             contraception&#xD;
&#xD;
        These specific inclusion criteria will apply for the Avelumab arm in addition to the common&#xD;
        criteria.&#xD;
&#xD;
          1. Hematologic:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L,&#xD;
&#xD;
               2. Platelet count ≥ 100 × 109/L,&#xD;
&#xD;
               3. Hemoglobin ≥ 9 g/dL. (may have been transfused).&#xD;
&#xD;
          2. Hepatic:&#xD;
&#xD;
             a. Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range.&#xD;
&#xD;
          3. Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault&#xD;
             formula (or local institutional standard method)&#xD;
&#xD;
          4. Pregnancy test: Negative serum or urine pregnancy test at screening for women of&#xD;
             childbearing potential.&#xD;
&#xD;
          5. Contraception: Highly effective contraception for both male and female subjects&#xD;
             throughout the study and for at least 30 days after last Avelumab treatment&#xD;
             administration if the risk of conception exists.&#xD;
&#xD;
        Common Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women,&#xD;
&#xD;
          2. Participation in another clinical trial with any investigative drug within 30 days&#xD;
             prior to study enrolment,&#xD;
&#xD;
          3. Prior history of hematopoietic stem cell transplantation (autologous or allogenic)&#xD;
&#xD;
          4. Cardiovascular disease:&#xD;
&#xD;
               -  Stage II to IV congestive heart failure (CHF) as determined by the New York Heart&#xD;
                  Association (NYHA) classification system for heart failure.&#xD;
&#xD;
               -  Myocardial infarction within the previous 6 months&#xD;
&#xD;
               -  Symptomatic cardiac arrhythmia requiring treatment&#xD;
&#xD;
          5. Grade III or IV fluid retention&#xD;
&#xD;
          6. Known BCR-ABL kinase domain mutation&#xD;
&#xD;
          7. CML patient not in chronic phase at diagnosis&#xD;
&#xD;
          8. Individuals with an active malignancy&#xD;
&#xD;
          9. Known HIV-positivity&#xD;
&#xD;
        These specific exclusion criteria will apply for the pioglitazone arm in addition to the&#xD;
        common criteria.&#xD;
&#xD;
          1. Known osteoporosis with curative therapy (prophylactic therapy is not an exclusion&#xD;
             criteria)&#xD;
&#xD;
          2. Patient requiring anti-diabetic medication&#xD;
&#xD;
        These specific exclusion criteria will apply for the Avelumab arm in addition to the common&#xD;
        criteria:&#xD;
&#xD;
          1. IMMUNOSUPRESSANTS: Current use of immunosuppressive medication, EXCEPT for the&#xD;
             following:&#xD;
&#xD;
               1. intranasal, inhaled, topical steroids, or local steroid injection (e.g.,&#xD;
                  intra-articular injection);&#xD;
&#xD;
               2. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or&#xD;
                  equivalent;&#xD;
&#xD;
               3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication).&#xD;
&#xD;
          2. AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an&#xD;
             immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo-&#xD;
             or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.&#xD;
&#xD;
          3. ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell&#xD;
             transplantation.&#xD;
&#xD;
          4. INFECTIONS: Active infection requiring systemic therapy.&#xD;
&#xD;
          5. HIV/AIDS: Known history of testing positive for HIV or known acquired immunodeficiency&#xD;
             syndrome.&#xD;
&#xD;
          6. HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening&#xD;
             (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)&#xD;
&#xD;
          7. VACCINATION: Vaccination within 4 weeks of the first dose of Avelumab and while on&#xD;
             trials is prohibited except for administration of inactivated vaccines&#xD;
&#xD;
          8. HYPERSENSITIIVTY TO STUDY DRUG: Known prior severe hypersensitivity to investigational&#xD;
             product or any component in its formulations, including known severe hypersensitivity&#xD;
             reactions tomonoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3)&#xD;
&#xD;
          9. CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease:&#xD;
             cerebral vascular accident/stroke (&lt; 6 months prior to enrolment), myocardial&#xD;
             infarction (&lt; 6 months prior to enrolment), unstable angina, congestive heart failure&#xD;
             (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia&#xD;
             equiring medication.&#xD;
&#xD;
         10. OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI CTCAE&#xD;
             v. 4.03 Grade &gt; 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤&#xD;
             2 not constituting a safety risk based on investigator's judgment are acceptable.&#xD;
&#xD;
         11. Other severe acute or chronic medical conditions including immune colitis,&#xD;
             inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric&#xD;
             conditions including recent (within the past year) or active suicidal ideation or&#xD;
             behaviour; or laboratory abnormalities that may increase the risk associated with&#xD;
             study participation or study treatment administration or may interfere with the&#xD;
             interpretation of study results and, in the judgment of the investigator, would make&#xD;
             the patient inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe ROUSSELOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Versailles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laure MORISSET</last_name>
    <phone>003339239785</phone>
    <email>lmorisset@ch-versailles.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Martine GARDEMBAS</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine GARDEMBAS</last_name>
      <phone>02.41.35.44.75</phone>
      <email>MaGardembas@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pascale CONY.MAKHOUL</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale CONY.MAKHOUL</last_name>
      <phone>04.50.63.64.31</phone>
      <email>pconymakhoul@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thorsten BRAUN</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten BRAUN</last_name>
      <phone>01.48.95.54.58</phone>
      <email>Thorsten.braun@avc.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Etienne</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Etienne</last_name>
      <phone>05.56.33.04.76</phone>
      <email>G.Etienne@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyacynthe Johnson-Ansah</last_name>
      <phone>02.31.27.25.39</phone>
      <email>Johnsonansah-a@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc BERGER</last_name>
      <email>mberger@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROY Lydia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rousselot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Rousselot</last_name>
      <phone>01.39.63.89.09</phone>
      <email>phrousselot@ch-versailles.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COITEUX Valérie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amélie PENOT</last_name>
      <phone>05.55.05.66.42</phone>
      <email>Amelie.penot@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franck NICOLINI</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck NICOLINI</last_name>
      <phone>04.72.11.74.01</phone>
      <email>franck.nicolini@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut P Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHARBONNIER Aude</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viviane DUBRUILLE</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane DUBRUILLE</last_name>
      <phone>02.40.08.32.71</phone>
      <email>Viviane.dubruille@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence LEGROS</last_name>
      <phone>04.92.03.58.41</phone>
      <email>legros.l@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eric JOURDAN</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric JOURDAN</last_name>
      <phone>04.66.68.32.31</phone>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Source</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BENBRAHIM Omar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Delphine REA _St louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine REA</last_name>
      <phone>01.42.49.96.49</phone>
      <email>delphine.rea@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simona LAPUSAN_St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona LAPUSAN</last_name>
      <phone>01.49.28.34.42</phone>
      <email>Simona.lapusan@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cayssials</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Cayssials</last_name>
      <phone>: 05.49.44. 44.72</phone>
      <email>e.cayssials@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ESCOFFRE-BARBE Martine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie GLAISNER</last_name>
      <phone>01.47.11.15.30</phone>
      <email>Sylvie.glaisner@curie.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire contre le Cancer</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Françoise HUGUET</last_name>
      <phone>05.31.15.63.56</phone>
      <email>Huguet.françoise@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DARTIGEAS Caroline</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Philippe ROUSSELOT</investigator_full_name>
    <investigator_title>Clinical coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

